Yu QQ - Search Results

1

MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells.

Yu QQ, Wu H, Huang X, Shen H, Shu YQ, Zhang B, Xiang CC, Yu SM, Guo RH, Chen L. Yu QQ, et al. Among authors: yu sm. Biomed Pharmacother. 2014 Mar;68(2):155-61. doi: 10.1016/j.biopha.2014.01.005. Epub 2014 Jan 15. Biomed Pharmacother. 2014. PMID: 24486107

2

Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.

Yu S, Zhang Z, Zhang B, Shu Y, Wu H, Huang X, Yu Q, Guo R. Yu S, et al. Med Oncol. 2014 Jun;31(6):983. doi: 10.1007/s12032-014-0983-7. Epub 2014 May 17. Med Oncol. 2014. PMID: 24838432

3

Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.

Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, Yu Q, Yin Y, Guo R. Yu S, et al. Clin Lung Cancer. 2015 Mar;16(2):121-7. doi: 10.1016/j.cllc.2014.09.007. Epub 2014 Sep 30. Clin Lung Cancer. 2015. PMID: 25450874 Clinical Trial.

4

Isolated gastric recurrence from ovarian carcinoma: A case report.

Liu Q, Yu QQ, Wu H, Zhang ZH, Guo RH. Liu Q, et al. Among authors: yu qq. Oncol Lett. 2015 Mar;9(3):1173-1176. doi: 10.3892/ol.2015.2887. Epub 2015 Jan 19. Oncol Lett. 2015. PMID: 25663876 Free PMC article.

5

MicroRNA-1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib.

Yu Q, Liu Y, Wen C, Zhao Y, Jin S, Hu Y, Wang F, Chen L, Zhang B, Wang W, Zhu Q, Guo R. Yu Q, et al. Oncol Lett. 2018 Jan;15(1):963-971. doi: 10.3892/ol.2017.7378. Epub 2017 Nov 9. Oncol Lett. 2018. PMID: 29399158 Free PMC article.

6

Down-regulation of IFIT3 protects liver from ischemia-reperfusion injury.

Guan G, Shen Y, Yu Q, Liu H, Zhang B, Guo Y, Zhu X, Li Z, Rao W, Zhuang L, Zang Y. Guan G, et al. Int Immunopharmacol. 2018 Jul;60:170-178. doi: 10.1016/j.intimp.2018.04.045. Epub 2018 May 4. Int Immunopharmacol. 2018. PMID: 29734133

7

Downregulation of miR-140 is Correlated with Poor Prognosis and Progression of Thyroid Cancer.

Yu Q, Sun W, Hua H, Chi Y, Liu X, Dong A, Sun Y, Zhang J, Guan G. Yu Q, et al. Endocr Metab Immune Disord Drug Targets. 2021;21(4):749-755. doi: 10.2174/1871530320666200724180742. Endocr Metab Immune Disord Drug Targets. 2021. PMID: 32713344

8

Overexpression of miR-127 Predicts Poor Prognosis and Contributes to the Progression of Papillary Thyroid Cancer by Targeting REPIN1.

Sun Y, Sun W, Hua H, Zhang J, Yu Q, Wang J, Liu X, Dong A. Sun Y, et al. Horm Metab Res. 2021 Mar;53(3):197-203. doi: 10.1055/a-1322-3160. Epub 2020 Dec 18. Horm Metab Res. 2021. PMID: 33339069

9

Serum Extracellular Vesicles Attenuate Cardiomyocyte Injury Induced by Hypoxic/Reoxygenation by Regulating miR-1229-5p.

Jin Y, Liu G, Yu Q, Ma S, Chang M. Jin Y, et al. Tohoku J Exp Med. 2022 Aug 6;258(1):35-41. doi: 10.1620/tjem.2022.J048. Epub 2022 Jun 16. Tohoku J Exp Med. 2022. PMID: 35705319 Free article.

10

[Diagnostic value of p53 protein examination in lung cancer through preoperative fibro-optic bronchoscope brushing and biospy].

Yu Q, Xiao Z, Liu G. Yu Q, et al. Zhonghua Zhong Liu Za Zhi. 1998 Nov;20(6):445-7. Zhonghua Zhong Liu Za Zhi. 1998. PMID: 10920941 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters